GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 52.05 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-03-06
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was -1.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 52.05K shares, a 108.20% increase from fiscal 2024.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 25.00K shares, a 118.99% increase from fiscal 2023.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 11.42K shares, a 67.07% increase from fiscal 2022.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 6.83K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | 52.05K shares 10-K · filed 2026-03-02 | |
| 2025-09-30 | 52.05K shares 10-Q/A · filed 2026-03-06 | ||
| 2024-12-31 | -1.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | 25.00K shares 10-K · filed 2026-03-02 | |
| 2024-09-30 | 25.00K shares 10-Q · filed 2024-11-14 | ||
| 2023-12-31 | 11.42K shares 10-K · filed 2025-02-21 | ||
| 2022-12-31 | 6.83K shares 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |